Skip to main content

Advertisement

Log in

Risk of Atrial Fibrillation Associated with Use of Bisphosphonates and Other Drugs Against Osteoporosis: A Cohort Study

  • Published:
Calcified Tissue International Aims and scope Submit manuscript

Abstract

We studied the association between bisphosphonate use and risk of atrial fibrillation or flutter and the effect of confounders such as heart and lung disease in a nationwide retrospective cohort from Denmark. All users of bisphosphonates and other drugs against osteoporosis between 1996 and 2006 (n = 103,562) were the exposed group and three age- and gender-matched controls from the general population (n = 310,683) were the nonexposed group. The main outcome measure was atrial fibrillation or atrial flutter. Before initiation of treatment against osteoporosis, no excess of atrial fibrillation or flutter was present for any drug except for etidronate (OR = 1.22, 95% CI 1.15–1.29). After initiation of treatment, raloxifene was not associated with any excess risk of atrial fibrillation (OR = 0.98, 95% CI 0.72–1.33). Etidronate (HR = 1.08, 95% CI 1.02–1.14) and alendronate (HR = 1.09, 95% CI 1.00–1.20) were associated with an excess risk of atrial fibrillation after treatment start if statistical adjustments were made for cardiovascular disease. However, this association disappeared upon statistical adjustment for chronic obstructive pulmonary disease (COPD) (etidronate HR = 1.04, 95% CI 0.98–1.10; alendronate HR = 1.05, 95% CI 0.96–1.15). In patients using etidronate (12.5% vs. 3.8%) and alendronate (11.4% vs. 4.6%) major differences were present in prevalence of COPD at start of treatment compared to matched controls. In conclusion, oral bisphosphonates do not seem to be associated with an excess risk of atrial fibrillation. Any excess risk seen in prior studies may be due to confounding from COPD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Black D, Delmas P, Eastell R, Reid I, Boonen S, Cauley J et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822

    Article  CAS  PubMed  Google Scholar 

  2. Lyles K, Colon-Emeric C, Magaziner J, Adachi J, Pieper C, Mautalen C et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809

    Article  CAS  PubMed  Google Scholar 

  3. Abrahamsen B, Eiken P, Brixen K (2009) Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med 265:581–592

    Article  CAS  PubMed  Google Scholar 

  4. Charlson M, Pompei P, Ales K, MacKenzie C (1987) A method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40:373–383

    Article  CAS  PubMed  Google Scholar 

  5. Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM (2008) Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 168:826–831

    Article  CAS  PubMed  Google Scholar 

  6. Sorensen H, Christensen S, Mehnert F, Pedersen L, Chapurlat R, Cummings S et al (2008) Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 336:813–816

    Article  PubMed  Google Scholar 

  7. Bunch TJ, Anderson JL, May HT, Muhlestein JB, Horne BD, Crandall BG et al (2009) Relation of bisphosphonate therapies and risk of developing atrial fibrillation. Am J Cardiol 103:824–828

    Article  CAS  PubMed  Google Scholar 

  8. Loke Y, Jeevanantham V, Singh S (2009) Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf 32:219–228

    Article  CAS  PubMed  Google Scholar 

  9. Frost L, Vestergaard P, Mosekilde L (2004) Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study. Arch Intern Med 164:1675–1678

    Article  PubMed  Google Scholar 

  10. Frost L, Vestergaard P (2004) Alcohol and risk of atrial fibrillation or flutter: a cohort study. Arch Intern Med 164:1993–1998

    Article  PubMed  Google Scholar 

  11. Frost L, Hune L, Vestergaard P (2005) Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Med 118:489–495

    Article  PubMed  Google Scholar 

  12. Vestergaard P, Mosekilde L (2003) Hyperthyroidism, bone mineral, and fracture risk—a meta-analysis. Thyroid 13:585–593

    Article  PubMed  Google Scholar 

  13. Tanko LB, Bagger YZ, Christiansen C (2003) Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif Tissue Int 73:15–20

    Article  CAS  PubMed  Google Scholar 

  14. Vestergaard P, Rejnmark L, Mosekilde L (2009) Hypertension is a risk factor for fractures. Calcif Tissue Int 84:103–111

    Article  CAS  PubMed  Google Scholar 

  15. Andersen T, Madsen M, Jørgensen J, Mellemkjær L, Olsen J (1999) The Danish National Hospital Register. Dan Med Bull 46:263–268

    CAS  PubMed  Google Scholar 

  16. Mosbech J, Jørgensen J, Madsen M, Rostgaard K, Thornberg K, Poulsen T (1995) The Danish National Patient Register: evaluation of data quality [in Danish]. Ugeskr Laeger 157:3741–3745

    CAS  PubMed  Google Scholar 

  17. Frost L, Vestergaard P, Mosekilde L, Mortensen L (2005) Trends in incidence and mortality in the hospital diagnosis of atrial fibrillation or flutter in Denmark, 1980–1999. Int J Cardiol 103:78–84

    Article  PubMed  Google Scholar 

  18. Vestergaard P, Rejnmark L, Mosekilde L (2005) Fracture risk associated with systemic and topical corticosteroids. J Intern Med 257:374–384

    Article  CAS  PubMed  Google Scholar 

  19. Vestergaard P, Mosekilde L (2003) Fracture risk associated with smoking—a meta-analysis. J Intern Med 254:572–583

    Article  CAS  PubMed  Google Scholar 

  20. Dimal H, Domej W, Leb G, Lau K (2001) Bone loss in patients with untreated chronic obstructive pulmonary disease is mediated by an increase in bone resorption associated with hypercapnia. J Bone Miner Res 16:2132–2141

    Article  Google Scholar 

  21. Forli L, Halse J, Haug E, Bjortuft O, Vatn M, Kofstad J et al (2004) Vitamin D deficiency, bone mineral density and weight in patients with advanced pulmonary disease. J Intern Med 256:56–62

    Article  CAS  PubMed  Google Scholar 

  22. De Laet C, Kanis J, Oden A, Johanson H, Johnell O, Delmas P et al (2005) Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 16:1330–1338

    Article  PubMed  Google Scholar 

  23. Hanrahan JP, Grogan DR, Baumgartner RA, Wilson A, Cheng H, Zimetbaum PJ et al (2008) Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol. Medicine (Baltimore) 87:319–328

    Article  CAS  Google Scholar 

Download references

Acknowledgement

This study was funded by an unrestricted grant from Servier Denmark and the Dandy Foundation. None of the sponsors had any role in obtaining data, analyzing data, or writing the report.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Peter Vestergaard.

Additional information

The authors have stated that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vestergaard, P., Schwartz, K., Pinholt, E.M. et al. Risk of Atrial Fibrillation Associated with Use of Bisphosphonates and Other Drugs Against Osteoporosis: A Cohort Study. Calcif Tissue Int 86, 335–342 (2010). https://doi.org/10.1007/s00223-010-9349-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00223-010-9349-0

Keywords

Navigation